GSK, Genmab report strong ofatumumab data

So far, it looks like GlaxoSmithKline's $2.1 billion deal for HuMax-CD20 was money well spent. Inerim data from a Phase III study showed that the drug--now known as ofatumumab--met primary and secondary endpoints in two groups of chronic lymphocytic leukemia patients who did not respond to either methotrexate or TNF-alpha antagonist therapy. More than half of the subjects who received ofatumumab responded to the drug, and now the companies are hoping to submit the drug the FDA and EMEA this year. The drug is also being studied in patients with non-Hodgkin's lymphoma, rheumatoid arthritis and multiple sclerosis.

- see this release on the results
- here's the WSJ report

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.